N PFS by investigator assessment.* Univariate analysis Baseline variable Remedy (lenalidomide versus IC) MIPI-based qualities MIPI score at diagnosis (high versus low/intermediate) MIPI score at baseline (high versus low/intermediate) Age, years (65 vs. 65) ECOG PS (two vs. 0) LDH (higher versus low/normal) WBC (10 9 109/l vs. ten 9 109/l) Other patient characteristics Sex (female versus male) MCL stage at diagnosis (III/IV versus I/II) Tumour burden (low versus high)Bulky disease (yes versus no)Bone marrow assessment (negative versus indeterminate/positive)** Renal function (normal versus moderate/severe insufficiency) Prior treatment history Time from MCL diagnosis to very first dose (three versus 3 years) Variety of prior systemic antilymphoma therapies (three versus three) Disease status to last prior therapy (relapsed versus refractory) Time from last prior therapy to 1st dose (six vs. six months) Time due to the fact final rituximab to first dose (230 vs. 230 days) Prior HDT (yes versus no)�� Prior SCT (yes versus no) HR (95 CI) 05 (087) 17 21 12 16 20 15 06 01 01 10 02 00 05 11 07 04 09 08 06 (120) (173) (058) (096) (197) (181) (028) (062) (008) (081) (040) (034) (044) (116) (083) (058) (097) (082) (069) P worth 005 009 001 019 053 001 017 048 061 055 063 006 003 080 009 075 034 027 030 037 Multivariate analysis HR (95 CI) 02 (082) — 11 (107) — — 22 (151) — — — — 17 (113) — — — 15 (198) — 08 (077) — — — P worth 001 — 052 — — 001 — — — — 045 — — — 005 — 032 — — –95 CI, 95 self-confidence interval; CR, total response; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group functionality status; HDT, high-dose therapy; HR, hazard ratio; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; MIPI, MCL International Prognostic Index; PFS, progression-free survival; SCT, stem cell transplantation; WBC, white blood cell count. *Variables with P value 00 within the univariate analysis have been chosen for multivariate analysis. Final variables had been selected applying a stepwise selection strategy with entry level = 00 and remain level = 05. Multivariate survival analysis utilizing Cox’s regression model was estimated employing 162 sufferers. MIPI score = 03535 * age + 0978 * (if ECOG PS 1) + 167 * log10 (LDH/upper limit of standard) + 0393 * log10 (WBC per 10/l). High LDH was three lkat/l for individuals aged 60 years and three lkat/l for all those aged 60 years; low LDH was 1 lkat/l; typical was defined per neighborhood laboratory criteria. �High tumour burden was defined by at the least 1 lesion 5 cm in diameter or 3 lesions 3 cm in diameter by central radiology evaluation. ulky disease was defined by no less than one particular lesion 7 cm in the longest diameter by central radiology assessment.24(S)-Hydroxycholesterol Endogenous Metabolite **For estimation of bone marrow involvement by neighborhood pathologist, unfavorable was defined as obtaining no aggregates or only a few well-circumscribed lymphoid aggregates, indeterminate bone marrow was defined as having an enhanced number/size of lymphoid aggregates without the need of overt malignancy, and constructive was defined as an unequivocal malignancy.Chaetocin Protocol Regular renal function was defined as CrCl of 60 ml/min; moderate insufficiency had CrCl 30 to 60 ml/min but not requiring dialysis; severe insufficiency had CrCl 30 ml/min.PMID:23618405 two sufferers had serious insufficiency in this study. Relapse incorporated individuals with very best response to last therapy of CR, unconfirmed CR, or partial response. ��HDT was defined as SCT, hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone plus methotrexate an.
